Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 227-645-2 | CAS number: 5921-65-3
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Repeated dose toxicity: oral
Administrative data
- Endpoint:
- short-term repeated dose toxicity: oral
- Remarks:
- Combined Repeated Dose Toxicity Study with the Reproductive/Developmental Toxicity Screening Study
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- 2017-01-26 to 2017-09-20
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- guideline study
Cross-reference
- Reason / purpose for cross-reference:
- reference to same study
Reference
- Endpoint:
- screening for reproductive / developmental toxicity
- Remarks:
- Combined Repeated Dose Toxicity Study with the Reproductive/Developmental Toxicity Screening Study
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- 2017-01-26 to 2017-09-20
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- guideline study
- Reason / purpose for cross-reference:
- reference to same study
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 422 (Combined Repeated Dose Toxicity Study with the Reproduction / Developmental Toxicity Screening Test)
- Version / remarks:
- 29 July 2016
- Deviations:
- no
- GLP compliance:
- yes (incl. QA statement)
- Limit test:
- no
- Species:
- rat
- Strain:
- Sprague-Dawley
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source:
Crl:CD(SD) rat /Charles River (UK) Ltd.
- Age at study initiation:
Males: 69 to 76 days old, Females: 83 to 90 days old.
- Weight at study initiation:
Males: 341 to 400 g, Females: 241 to 297 g.
- Housing:
polycarbonate body with a stainless steel mesh lid. used during the acclimatization, pre-pairing, treatment, gestation, littering and lactation periods.
Grid bottomed polypropylene cages were used during pairing.
Number of animals per cage: Pre-pairing up to five animals of one sex; Pairing one male and one female; Males after mating up to five animals;
Gestation one female; Lactation one female + litter
- Diet (e.g. ad libitum):
SDS VRF1 Certified pelleted ad libitum
- Water (e.g. ad libitum):
ad libitum, from the public supply via polycarbonate bottles with sipper tubes.
- Acclimation period:
Males: Six days before commencement of treatment ; Females: 20 days before commencement of treatment.
DETAILS OF FOOD AND WATER QUALITY:
The diet contained no added antibiotic or other chemotherapeutic or prophylactic agent.
Certificates of analysis for the diet are scrutinized and approved before any batch of diet was released for use.
Certificates of analysis were routinely provided by the water supplier.
ENVIRONMENTAL CONDITIONS
- Temperature (°C):
20-24ºC
- Humidity (%):
40-70%
- Air changes (per hr):
- Photoperiod (hrs dark / hrs light):
12 hours light : 12 hours dark
IN-LIFE DATES: From: 2017-05-03 To: 2017-07-02 - Route of administration:
- oral: gavage
- Vehicle:
- corn oil
- Details on exposure:
- - PREPARATION OF DOSING SOLUTIONS:
- VEHICLE
- Justification for use and choice of vehicle (if other than water): Standard vehicle according to guideline
- Concentration in vehicle: 8, 16, 32 mg/mL
- Amount of vehicle (if gavage): 5 mL - Details on mating procedure:
- - M/F ratio per cage: 1:1 from within the same treatment groups.
- Length of cohabitation: up to two weeks.
- Proof of pregnancy: sperm in the vaginal smear.
- After successful mating each pregnant female was caged (how): individually in solid (polycarbonate) bottom cages - Analytical verification of doses or concentrations:
- yes
- Details on analytical verification of doses or concentrations:
- The analytical procedure was successfully validated with respect to specificity of chromatographic analysis, limit of detection and quantification, linearity of detector response, repeatability, method accuracy and precision.
The homogeneity and stability was confirmed for Caprinoguanamine in corn oil formulations at nominal concentrations of 1 mg/mL and 200 mg/mL during distribution between the bottles, during magnetic stirring for 2 hours, ambient temperature storage for 1 day and refrigerated storage for up to 15 days.
The mean concentrations of Caprinoguanamine in test formulations analyzed for the study were within ±6% of nominal concentrations, confirming the accurate preparation of these formulations. - Duration of treatment / exposure:
- Males: Two weeks before pairing up to necropsy after a minimum of five weeks of treatment (animals were killed in Week 6).
Females Two weeks before pairing, then throughout pairing and gestation until Day 13 of lactation. - Frequency of treatment:
- Once daily at approximately the same time each day.
Animals were not dosed if parturition was in progress at the scheduled time of administration. - Details on study schedule:
- F1 animals were not mated (screening study)
- Dose / conc.:
- 0 mg/kg bw/day (nominal)
- Dose / conc.:
- 40 mg/kg bw/day (nominal)
- Dose / conc.:
- 80 mg/kg bw/day (nominal)
- Dose / conc.:
- 160 mg/kg bw/day (nominal)
- No. of animals per sex per dose:
- 10 males and 10 females
- Control animals:
- yes, concurrent vehicle
- Details on study design:
- - Dose selection rationale:
- Rationale for animal assignment (if not random):
Estrous cycles were evaluated prior to treatment. After 14 days evaluation, animals that failed to exhibit typical 4-5 day cycles were not allocated to the study.
On Day 1 of study all animals were weighed and body weights were reviewed by Study Management before dosing commenced to ensure that variations in
body weight of animals did not exceed ±20% of the mean for each sex. The groups were adjusted to reduce inter-/intra-group variation. - Parental animals: Observations and examinations:
- CAGE SIDE OBSERVATIONS: Yes
- Time schedule: Animals were inspected visually at least twice daily for evidence of ill-health or reaction to treatment.
- Cage side observations: Any deviation from normal was recorded at the time in respect of nature and severity, date and time of onset, duration and progress of the observed condition, as appropriate.
DETAILED CLINICAL OBSERVATIONS: Yes
- Time schedule: Before treatment commenced and during each week of treatment and on Days 0, 7, 14 and 20 after mating and Days 1, 6 and 12 of lactation, detailed physical examination and arena observations were performed on each animal.
BODY WEIGHT: Yes
- Time schedule for examinations: males: Before dosing on the day treatment commenced (Day 1) and weekly thereafter. On the day prior to necropsy.
females: Before dosing on the day treatment commenced (Day 1) and weekly before pairing. Days 0, 7, 14 and 20 after mating. Day 1, 4, 7 and 13 of lactation. On the day prior to necropsy.
FOOD CONSUMPTION AND COMPOUND INTAKE: not applicable, no feeding study
WATER CONSUMPTION AND COMPOUND INTAKE: not applicable, no drinking water study - Oestrous cyclicity (parental animals):
- Daily for 15 days before pairing.
For four days before scheduled termination (nominally Days 11 to 14 of lactation). - Sperm parameters (parental animals):
- For the assessment of the testes, a detailed qualitative examination was made, taking into account the tubular stages of the spermatogenic cycle.
The examination was conducted in order to identify treatment related effects such as missing germ cell layers or types, retained spermatids, multinucleate or apoptotic germ cells and sloughing of spermatogenic cells in the
lumen. Any cell- or stage-specificity of testicular findings was noted. - Litter observations:
- PARAMETERS EXAMINED
The following parameters were examined in F1 offspring:
number and sex of pups, stillbirths, live births, postnatal mortality, presence of gross anomalies, body weight Days 1, 4, 7 and 13 post partum
Ano-genital distance Day 1 - all F1 offspring.
Nipple/areolae count Day 13 of age - male offspring.
Thyroid Hormone Analysis:
Day 4 of age: F1 offspring, two females per litter: one for T4 (serum) and one for TSH (plasma)
Day 13 of age: F1 offspring, two males and two females per litter: two for T4 (serum) where possible one male and one female and two for TSH (plasma) where possible one male and one female
GROSS EXAMINATION OF DEAD PUPS:
yes, for external and internal abnormalities - Postmortem examinations (parental animals):
- SACRIFICE
- Male animals: All surviving animals, after week 5 investigations completed.
- Maternal animals: Day 25 after mating F0 females failing to produce a viable litter, all other females day 14 of lactation.
GROSS NECROPSY
- After a review of the history of each animal, a full macroscopic examination of the tissues was performed.
All external features and orifices were examined visually.
HISTOPATHOLOGY / ORGAN WEIGHTS
The five lowest numbered surviving males and the first five lactating females with a surviving litter per group at scheduled termination were subject to pathology procedures: The tissues indicated in Table [1] were prepared for microscopic examination and weighed, respectively.
Pathology procedures for remaining F0 males and females per group is outlined in Table 2 - Postmortem examinations (offspring):
- SACRIFICE
- The F1 offspring: Premature deaths: Where possible, a fresh macroscopic examination (external and internal) with an assessment of stomach for milk content was performed.
All animals were subject to an external macroscopic examination; particular attention was paid to the external genitalia.
Thyroid glands were preserved from one male and one female in each litter.
- Statistics:
- A parametric analysis was performed if Bartlett's test for variance homogeneity (Bartlett 1937) was not significant at the 1% level. For pretreatment data, analysis of variance was used to test for any group differences. Where this was significant (p<0.05) inter group comparisons using t-tests, with the error mean square from the one-way analysis of variance, were made. For all other comparisons the F1 approximate test was applied.
If the F1 approximate test for monotonicity of dose-response was not significant at the 1% level, Williams' test for a monotonic trend was applied.
If the F1 approximate test was significant, suggesting that the dose response was not monotone, Dunnett's test (Dunnett 1955, 1964) was performed instead. A non-parametric analysis was performed if Bartlett's test was still significant at the 1% level following both logarithmic and square-root transformations. For pretreatment data, Kruskal-Wallis’ test (Kruskal and Wallis 1952, 1953) was used to test for any group differences. Where this was significant (p<0.05) inter group comparisons using Wilcoxon rank sum tests (Wilcoxon 1945) were made. For all other comparisons the H1 approximate test, the non-parametric equivalent of the F1 test described above, was applied.
For grip strength, motor activity, clinical pathology data, if 75% of the data (across all groups) were the same value, for example c, Fisher’s exact tests (Fisher 1973) were performed.
For organ weight data, analysis of covariance was performed using terminal body weight as covariate (Angervall and Carlstrom, 1963), unless non-parametric methods were applied.
Significant differences between the groups compared were expressed at the 5% (p<0.05) or 1% (p<0.01) level. - Reproductive indices:
- Percentage mating (%)
Conception rate (%)
Fertility index (%)
Gestation index (%) - Offspring viability indices:
- Post-implantation survival index (%)
Live birth index (%)
Viability index (%)
Lactation index (%) - Clinical signs:
- no effects observed
- Description (incidence and severity):
- Parental (F0): Clinical condition, behaviour in the arena, sensory reactivity, grip strength and motor activity were unaffected by treatment.
- Mortality:
- no mortality observed
- Description (incidence):
- Parental (F0): No animals died prematurely
- Body weight and weight changes:
- no effects observed
- Description (incidence and severity):
- Parental (F0):
Male body weight gains during the last two weeks of treatment for animals receiving the test item at all doses were lower than controls.
This resulted in lower overall weight gains (Day 1 to 38) in these groups (96, 95 and 85% of control for males receiving 40, 80 or 160 mg/kg/day, respectively).
Females receiving 160 mg/kg/day had low body weight gains, when compared to controls, throughout the gestational period and subsequently a slightly lower gain throughout lactation.
These reductions in body weight gain were considered not of sufficient magnitude to be considered adverse. - Food efficiency:
- not examined
- Ophthalmological findings:
- not examined
- Haematological findings:
- no effects observed
- Description (incidence and severity):
- Parental (F0):
Haematological investigations did not reveal any findings that were attributed to treatment - Clinical biochemistry findings:
- no effects observed
- Description (incidence and severity):
- Parental (F0):
The biochemical examination of the blood plasma revealed slightly low plasma potassium, calcium, glucose, cholesterol and triglyceride concentrations in males receiving 40, 80 or 160 mg/kg/day.
Females receiving 40, 80 or 160 mg/kg/day had slightly higher plasma bile acid concentrations; these variations were in the absence of a dose dependent trend. - Urinalysis findings:
- not examined
- Behaviour (functional findings):
- no effects observed
- Description (incidence and severity):
- Behaviour in the arena, sensory reactivity, grip strength and motor activity were unaffected by treatment.
- Immunological findings:
- not examined
- Organ weight findings including organ / body weight ratios:
- no effects observed
- Histopathological findings: non-neoplastic:
- effects observed, non-treatment-related
- Description (incidence and severity):
- Changes related to treatment with Caprinoguanamine were seen in the liver of males.
Minimal to moderate periportal hepatocellular vacuolation, was seen in most males at all doses of Caprinoguanamine, and at minimal to slight severity in two control males. - Histopathological findings: neoplastic:
- no effects observed
- Reproductive function: oestrous cycle:
- no effects observed
- Description (incidence and severity):
- Estrous cyclicity, pre-coital interval, fertility, mating performance, gestation length and index were unaffected by the administration of Caprinoguanamine at all dose levels.
There was no effect of treatment on the number of implantations or litter size. - Reproductive function: sperm measures:
- no effects observed
- Description (incidence and severity):
- Seminiferous tubules were evaluated with respect to their stage in the spermatogenic cycle and the integrity of the various cell types present within the different stages.
No cell or stage abnormalities were noted. - Reproductive performance:
- no effects observed
- Description (incidence and severity):
- Reproductive performance, fertility and offspring survival were unaffected by parental treatment.
There was no effect of treatment on the number of implantations, litter size, or the growth of the offspring. - Key result
- Dose descriptor:
- NOAEL
- Effect level:
- 160 mg/kg bw/day (nominal)
- Based on:
- test mat.
- Sex:
- male/female
- Basis for effect level:
- other: highest tested dose
- Critical effects observed:
- no
- Clinical signs:
- no effects observed
- Description (incidence and severity):
- The clinical condition of the offspring, litter size, offspring survival and sex ratio were unaffected by parental treatment.
- Mortality / viability:
- no mortality observed
- Description (incidence and severity):
- Offspring survival and sex ratio were unaffected by parental treatment.
- Body weight and weight changes:
- effects observed, treatment-related
- Description (incidence and severity):
- In the 160 mg/kg/day group, male and female offspring body weights were marginally low on Day 1 of age, when compared with the controls; subsequent weight gain was marginally low.
There was no effect of treatment on the mean body weights of male and female offspring on Day 1 of age at 40 or 80 mg/kg/day. - Ophthalmological findings:
- not examined
- Haematological findings:
- not examined
- Clinical biochemistry findings:
- no effects observed
- Description (incidence and severity):
- There was no effect of treatment on the circulating levels of thyroxine (T4) in the Day 13 male and female offspring.
- Urinalysis findings:
- not examined
- Sexual maturation:
- no effects observed
- Description (incidence and severity):
- Ano-genital distances of both male and female offspring on Day 1 of age and nipple counts on Day 13 of age showed no adverse effects from parental treatment.
- Organ weight findings including organ / body weight ratios:
- not examined
- Gross pathological findings:
- no effects observed
- Description (incidence and severity):
- Macroscopic examination of offspring that died prior to the scheduled termination or were killed on Day 13 of age did not reveal any findings that were considered related to parental treatment at any dose level.
- Histopathological findings:
- not examined
- Other effects:
- not examined
- Behaviour (functional findings):
- not examined
- Developmental immunotoxicity:
- not examined
- Key result
- Dose descriptor:
- NOAEL
- Generation:
- F1
- Effect level:
- 160 mg/kg bw/day (nominal)
- Based on:
- test mat.
- Sex:
- male/female
- Basis for effect level:
- other: highest tested dose
- Key result
- Reproductive effects observed:
- no
- Conclusions:
- The no-observed-adverse-effect-level (NOAEL) for systemic toxicity and also for reproductive/developmental toxicity was considered to be 160 mg/kg/day.
- Executive summary:
In a Combined Repeated Dose Toxicity Study with the Reproduction / Developmental Toxicity Screening study according to OECD guideline 422, Caprinoguanamine (ca. 98 % a.i) was administered to 10 Sprague-Dawley rats /sex/ at dose levels of 0, 40, 80 and 160 mg/kg bw/day by gavage.
Males were treated daily for two weeks before pairing, up to necropsy after a minimum of five consecutive weeks. Females were treated daily for two weeks before pairing, throughout pairing, gestation and until Day 13 of lactation.
Oral gavage administration of Caprinoguanamine for five weeks was generally well tolerated in males at dose levels of 40, 80 or 160 mg/kg/day but did result in a higher incidence and severity of periportal hepatocellular vacuolation in the liver at all dose levels when compared with the controls. For detailed information refer to repeated dose toxicity.
F1 Litter responses
The clinical condition of the offspring, litter size, offspring survival and sex ratio were unaffected by parental treatment.
Ano-genital distances of both male and female offspring on Day 1 of age and nipple counts on Day 13 of age showed no adverse effects from parental treatment.
In the 160 mg/kg/day group, male and female offspring body weights were marginally low on Day 1 of age, when compared with the controls; subsequent weight gain was marginally low. There was no effect of treatment on the mean body weights of male and female offspring on Day 1 of age at 40 or 80 mg/kg/day.
Macroscopic examination of offspring that died prior to the scheduled termination or were killed on Day 13 of age did not reveal any findings that were considered related to parental treatment at any dose level.
Administration of Caprinoguanamine to females for two weeks before pairing, throughout gestation and up to Day 14 of lactation was also generally well tolerated with no test item related microscopic pathology changes detected. Reproductive performance, fertility and offspring survival were unaffected by parental treatment. There was no effect of treatment on the number of implantations, litter size, or the growth of the offspring.
In the context of this study, Caprinoguanamine showed no evidence of being an endocrine disruptor.
The no-observed-adverse-effect-level (NOAEL) for systemic toxicity and also for reproductive/ developmental toxicity was considered to be 160 mg/kg/day.
Data source
Reference
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 2 018
- Report date:
- 2018
Materials and methods
Test guideline
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 422 (Combined Repeated Dose Toxicity Study with the Reproduction / Developmental Toxicity Screening Test)
- Version / remarks:
- 2016-06-29
- Deviations:
- no
- GLP compliance:
- yes (incl. QA statement)
- Limit test:
- no
Test material
- Reference substance name:
- 6-nonyl-1,3,5-triazine-2,4-diamine
- EC Number:
- 227-645-2
- EC Name:
- 6-nonyl-1,3,5-triazine-2,4-diamine
- Cas Number:
- 5921-65-3
- Molecular formula:
- C12H23N5
- IUPAC Name:
- 6-nonyl-1,3,5-triazine-2,4-diamine
- Test material form:
- solid: bulk
Constituent 1
Test animals
- Species:
- rat
- Strain:
- Sprague-Dawley
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: Crl:CD(SD) rat /Charles River (UK) Ltd.
- Age at study initiation: Males: 69 to 76 days old, Females: 83 to 90 days old.
- Weight at study initiation: Males: 341 to 400 g, Females: 241 to 297 g.
- Housing: polycarbonate body with a stainless steel mesh lid. used during the acclimatization, pre-pairing, treatment, gestation, littering and lactation periods.
Grid bottomed polypropylene cages were used during pairing.
Number of animals per cage: Pre-pairing up to five animals of one sex; Pairing one male and one female; Males after mating up to five animals;
Gestation one female; Lactation one female + litter
- Diet (e.g. ad libitum): SDS VRF1 Certified pelleted ad libitum
- Water (e.g. ad libitum): ad libitum, from the public supply via polycarbonate bottles with sipper tubes.
- Acclimation period: Males: Six days before commencement of treatment ; Females: 20 days before commencement of treatment.
DETAILS OF FOOD AND WATER QUALITY:
The diet contained no added antibiotic or other chemotherapeutic or prophylactic agent.
Certificates of analysis for the diet are scrutinized and approved before any batch of diet was released for use.
Certificates of analysis were routinely provided by the water supplier.
ENVIRONMENTAL CONDITIONS
- Temperature (°C): 20-24ºC
- Humidity (%): 40-70%
- Air changes (per hr):
- Photoperiod (hrs dark / hrs light): 12 hours light : 12 hours dark
IN-LIFE DATES: From: 2017-05-03 To: 2017-07-02
Administration / exposure
- Route of administration:
- oral: gavage
- Details on route of administration:
- Oral gavage using a suitably graduated syringe and a rubber catheter inserted via the mouth.
- Vehicle:
- corn oil
- Details on oral exposure:
- - PREPARATION OF DOSING SOLUTIONS:
- VEHICLE
- Justification for use and choice of vehicle (if other than water): Standard vehicle according to guideline
- Concentration in vehicle: 8, 16, 32 mg/mL
- Amount of vehicle (if gavage): 5 mL - Analytical verification of doses or concentrations:
- yes
- Details on analytical verification of doses or concentrations:
- The analytical procedure was successfully validated with respect to specificity of chromatographic analysis, limit of detection and quantification, linearity of detector response, repeatability, method accuracy and precision.
The homogeneity and stability was confirmed for Caprinoguanamine in corn oil formulations at nominal concentrations of 1 mg/mL and 200 mg/mL during distribution between the bottles, during magnetic stirring for 2 hours, ambient temperature storage for 1 day and refrigerated storage for up to 15 days.
The mean concentrations of Caprinoguanamine in test formulations analyzed for the study were within ±6% of nominal concentrations, confirming the accurate preparation of these formulations. - Duration of treatment / exposure:
- Males: Two weeks before pairing up to necropsy after a minimum of five weeks of treatment (animals were killed in Week 6).
Females Two weeks before pairing, then throughout pairing and gestation until Day 13 of lactation. - Frequency of treatment:
- Once daily at approximately the same time each day.
Animals were not dosed if parturition was in progress at the scheduled time of administration.
Doses / concentrationsopen allclose all
- Dose / conc.:
- 0 mg/kg bw/day (nominal)
- Dose / conc.:
- 40 mg/kg bw/day (nominal)
- Dose / conc.:
- 80 mg/kg bw/day (nominal)
- Dose / conc.:
- 160 mg/kg bw/day (nominal)
- No. of animals per sex per dose:
- 10 males and 10 females
- Control animals:
- yes, concurrent vehicle
- Details on study design:
- - Dose selection rationale:
- Rationale for animal assignment (if not random):
Estrous cycles were evaluated prior to treatment. After 14 days evaluation, animals that failed to exhibit typical 4-5 day cycles were not allocated to the study.
On Day 1 of study all animals were weighed and body weights were reviewed by Study Management before dosing commenced to ensure that variations in
body weight of animals did not exceed ±20% of the mean for each sex. The groups were adjusted to reduce inter-/intra-group variation. - Positive control:
- no
Examinations
- Observations and examinations performed and frequency:
- CAGE SIDE OBSERVATIONS: Yes
- Time schedule: Animals were inspected visually at least twice daily for evidence of ill-health or reaction to treatment.
- Cage side observations: Any deviation from normal was recorded at the time in respect of nature and severity, date and time of onset, duration and progress of the observed condition, as appropriate.
DETAILED CLINICAL OBSERVATIONS: Yes
- Time schedule: Before treatment commenced and during each week of treatment and on Days 0, 7, 14 and 20 after mating and Days 1, 6 and 12 of lactation,
detailed physical examination and arena observations were performed on each animal.
BODY WEIGHT: Yes
- Time schedule for examinations: males: Before dosing on the day treatment commenced (Day 1) and weekly thereafter. On the day prior to necropsy.
females: Before dosing on the day treatment commenced (Day 1) and weekly before pairing. Days 0, 7, 14 and 20 after mating. Day 1, 4, 7 and 13 of lactation. On the day prior to necropsy.
FOOD CONSUMPTION AND COMPOUND INTAKE: not applicable, no feeding study
FOOD EFFICIENCY:
- Body weight gain in kg/food consumption in kg per unit time X 100 calculated as time-weighted averages from the consumption and body weight gain data: No
WATER CONSUMPTION AND COMPOUND INTAKE (if drinking water study): not applicable, no drinking water study
OPHTHALMOSCOPIC EXAMINATION: No
HAEMATOLOGY: Yes
- Time schedule for collection of blood: at termination
- Anaesthetic used for blood collection: Yes, light general anesthesia induced by isoflurane
- Animals fasted: Yes; overnight
- How many animals: The five lowest numbered surviving males and the first five lactating females with a surviving litter, in each dose group.
- Parameters checked in table [No.1] were examined.
CLINICAL CHEMISTRY: Yes
- Time schedule for collection of blood: at termination
- Animals fasted: Yes overnight
- How many animals: The five lowest numbered surviving males and the first five lactating females with a surviving litter, in each dose group.
- Parameters checked in table [No.2] were examined.
URINALYSIS: No
NEUROBEHAVIOURAL EXAMINATION: Yes
- Time schedule for examinations: During Week 5 of treatment for males and at Day 7-9 of lactation for females
- Dose groups that were examined: five lowest numbered surviving males and the first five lactating females in each group
- Battery of functions tested: sensory activity / grip strength / motor activity
IMMUNOLOGY: No
THYROID HORMONE ANALYSIS.
- Time schedule for collection of blood: at termination, all surviving F0 adult males and females
- Anaesthetic used for blood collection: Yes, light general anesthesia induced by isoflurane
- Animals fasted: Yes; overnight
- How many animals: all surviving F0 adult males and females
Initially measurement of the serum samples of the adult males and the Day 13 offspring for thyroxine (T4) levels.
These examinations were undertaken and no effect of treatment was evident on the circulating levels of this hormone.
It was therefore not necessary to analyze any further samples for either T4 or TSH (thyroid stimulating hormone). - Sacrifice and pathology:
- GROSS PATHOLOGY: Yes
All adult animals were subject to a detailed necropsy.
F0 males After Week 5 investigations completed.
F0 females failing to produce a viable litter: Day 25 after mating.
F0 females Day 14 of lactation.
Pathology procedures for the five lowest numbered surviving males and the first five lactating females with a surviving litter per group at scheduled termination [Table 3]
Pathology procedures for remaining F0 males and females per group [Table 4]
HISTOPATHOLOGY: Yes (Table 3 and 4)
Tissue samples were dehydrated, embedded in paraffin wax and sectioned at a nominal four to five micron thickness.
For bilateral organs, sections of both organs were prepared.
A single section was prepared from each of the remaining tissues required.
Full List: [Table 3] The five lowest numbered surviving males and the first five lactating females with a surviving litter in Groups 1 and 4 at scheduled termination.
Liver: The five lowest numbered surviving males in Groups 2 and 3.
Abnormalities only: All remaining F0 animals. - Statistics:
- A parametric analysis was performed if Bartlett's test for variance homogeneity (Bartlett 1937) was not significant at the 1% level. For pretreatment data, analysis of variance was used to test for any group differences. Where this was significant (p<0.05) inter group comparisons using t-tests, with the error mean square from the one-way analysis of variance, were made. For all other comparisons the F1 approximate test was applied.
If the F1 approximate test for monotonicity of dose-response was not significant at the 1% level, Williams' test for a monotonic trend was applied.
If the F1 approximate test was significant, suggesting that the dose response was not monotone, Dunnett's test (Dunnett 1955, 1964) was performed instead. A non-parametric analysis was performed if Bartlett's test was still significant at the 1% level following both logarithmic and square-root transformations. For pretreatment data, Kruskal-Wallis’ test (Kruskal and Wallis 1952, 1953) was used to test for any group differences. Where this was significant (p<0.05) inter group comparisons using Wilcoxon rank sum tests (Wilcoxon 1945) were made. For all other comparisons the H1 approximate test, the non-parametric equivalent of the F1 test described above, was applied.
For grip strength, motor activity, clinical pathology data, if 75% of the data (across all groups) were the same value, for example c, Fisher’s exact tests (Fisher 1973) were performed.
For organ weight data, analysis of covariance was performed using terminal body weight as covariate (Angervall and Carlstrom, 1963), unless non-parametric methods were applied.
Significant differences between the groups compared were expressed at the 5% (p<0.05) or 1% (p<0.01) level.
Results and discussion
Results of examinations
- Clinical signs:
- no effects observed
- Description (incidence and severity):
- Parental (F0): Clinical condition, behaviour in the arena, sensory reactivity, grip strength and motor activity were unaffected by treatment.
- Mortality:
- no mortality observed
- Description (incidence):
- Parental (F0): No animals died prematurely
- Body weight and weight changes:
- no effects observed
- Description (incidence and severity):
- Parental (F0):
Male body weight gains during the last two weeks of treatment for animals receiving the test item at all doses were lower than controls.
This resulted in lower overall weight gains (Day 1 to 38) in these groups (96, 95 and 85% of control for males receiving 40, 80 or 160 mg/kg/day, respectively).
Females receiving 160 mg/kg/day had low body weight gains, when compared to controls, throughout the gestational period and subsequently a slightly lower gain throughout lactation.
These reductions in body weight gain were considered not of sufficient magnitude to be considered adverse. - Food efficiency:
- not examined
- Ophthalmological findings:
- not examined
- Haematological findings:
- no effects observed
- Description (incidence and severity):
- Parental (F0):
Haematological investigations did not reveal any findings that were attributed to treatment - Clinical biochemistry findings:
- no effects observed
- Description (incidence and severity):
- Parental (F0):
The biochemical examination of the blood plasma revealed slightly low plasma potassium, calcium, glucose, cholesterol and triglyceride concentrations in males receiving 40, 80 or 160 mg/kg/day.
Females receiving 40, 80 or 160 mg/kg/day had slightly higher plasma bile acid concentrations; these variations were in the absence of a dose dependent trend. - Urinalysis findings:
- not examined
- Behaviour (functional findings):
- no effects observed
- Description (incidence and severity):
- Behaviour in the arena, sensory reactivity, grip strength and motor activity were unaffected by treatment.
- Immunological findings:
- not examined
- Organ weight findings including organ / body weight ratios:
- no effects observed
- Description (incidence and severity):
- When compared with the controls, the evaluation of organ weights of males killed after five weeks of treatment revealed the following non dose related changes which were considered of uncertain relationship to treatment.
The weight of the levator ani-bulbocavernosus muscle complex (LABC) was marginally but statistically significantly high in males given 160 mg/kg/day.
The weight of the thyroids/parathyroids was marginally but statistically significantly high in males given 80 or 160 mg/kg/day. - Gross pathological findings:
- no effects observed
- Description (incidence and severity):
- The macroscopic examination performed after five weeks of treatment (males) or on Day 14 of lactation (females) did not reveal any test item-related changes.
The incidence and distribution of all findings were considered to be unrelated to treatment. - Histopathological findings: non-neoplastic:
- effects observed, treatment-related
- Description (incidence and severity):
- Changes related to treatment with Caprinoguanamine were seen in the liver of males.
Minimal to moderate periportal hepatocellular vacuolation, was seen in most males at all doses of Caprinoguanamine, and at minimal to slight severity in two control males. - Histopathological findings: neoplastic:
- no effects observed
- Details on results:
- The microscopic examination of the full list of examined tissues revealed that periportal hepatocellular vacuolation, typically a background change, was present at a higher incidence and severity in the livers of males receiving 40, 80 or 160 mg/kg/day of the test item. A mixed vacuolation was present in males given 160 mg/kg/day: in the periportal areas it was microvesicular, whereas at the edges of the liver lobes it was macrovesicular. In males given 40 or 80 mg/kg/day the vacuolation was more of the microvesicular type. Microvesicular lipidosis is usually indicative of more serious hepatic dysfunction but can also result from nutritional disturbances (Greaves 2007). There was no clear dose-dependency but a no observed effect level (NOEL) was not determined because the change was seen in males given the lowest dose of Caprinoguanamine. This change was considered not to represent an adverse effect of treatment since there was no effect on the clinical condition or survival of the animals and no signs of altered hepatic function as judged by clotting times and urea, protein and albumin levels.
Effect levels
- Key result
- Dose descriptor:
- NOAEL
- Effect level:
- 160 mg/kg bw/day (nominal)
- Based on:
- test mat.
- Sex:
- male/female
- Basis for effect level:
- other: highest tested dose
Target system / organ toxicity
- Key result
- Critical effects observed:
- no
Applicant's summary and conclusion
- Conclusions:
- The no-observed-adverse-effect-level (NOAEL) for systemic toxicity was considered to be 160 mg/kg/day.
- Executive summary:
In a Combined Repeated Dose Toxicity Study with the Reproduction / Developmental Toxicity Screening study according to OECD guideline 422, Caprinoguanamine (ca. 98 % a.i) was administered to 10 Sprague-Dawley rats /sex/ at dose levels of 0, 40, 80 and 160 mg/kg bw/day by gavage.
Males were treated daily for two weeks before pairing, up to necropsy after a minimum of five consecutive weeks. Females were treated daily for two weeks before pairing, throughout pairing, gestation and until Day 13 of lactation.
Parental (F0) responses
No animals died prematurely. Clinical condition, behaviour in the arena, sensory reactivity, grip strength and motor activity were unaffected by treatment. Salivation and chin rubbing were seen in association with dosing; such signs are common on studies dosed by the oral gavage route and are generally due to the taste of the formulations.
Male body weight gains during the last two weeks of treatment for animals receiving the test item at all doses were lower than controls. This resulted in lower overall weight gains (Day 1 to 38) in these groups (96, 95 and 85% of control for males receiving 40, 80 or 160 mg/kg/day, respectively). Females receiving 160 mg/kg/day had low body weight gains, when compared to controls, throughout the gestational period and subsequently a slightly lower gain throughout lactation. These reductions in body weight gain were considered not of sufficient magnitude to be considered adverse.
The food consumption of males receiving 160 mg/kg/day was slightly low in the first three weeks of treatment when compared with the controls. During the pre-pairing period, female food consumption was unaffected by treatment. However, during gestation, females receiving 160 mg/kg/day ate less food than the control group. Low food consumption was also seen in these females during lactation after Day 4. These minor variations in food consumption were considered non-adverse.
Estrous cyclicity, pre-coital interval, fertility, mating performance, gestation length and index were unaffected by the administration of Caprinoguanamine at all dose levels. There was no effect of treatment on the number of implantations or litter size.
Haematological investigations did not reveal any findings that were attributed to treatment.
The biochemical examination of the blood plasma revealed slightly low plasma potassium, calcium, glucose, cholesterol and triglyceride concentrations in males receiving 40, 80 or 160 mg/kg/day. Females receiving 40, 80 or 160 mg/kg/day had slightly higher plasma bile acid concentrations; these variations were in the absence of a dose dependent trend.
There was no effect of treatment on the circulating levels of thyroxine (T4) in adult males or in the Day 13 male and female offspring.
There were no changes in organ weights considered to be related to treatment
Macroscopic examination of the adult males and females did not reveal any test item-related changes, the incidence and distribution of all findings were considered to be unrelated to treatment.
Microscopic pathology revealed minimal to moderate periportal hepatocellular vacuolation in the liver of the majority of males receiving 40, 80 or 160 mg/kg/day. Similar findings were also recorded in two control males.
In conclusion, oral gavage administration of Caprinoguanamine for five weeks was generally well tolerated in males at dose levels of 40, 80 or 160 mg/kg/day but did result in a higher incidence and severity of periportal hepatocellular vacuolation in the liver at all dose levels when compared with the controls. Administration of Caprinoguanamine to females for two weeks before pairing, throughout gestation and up to Day 14 of lactation was also generally well tolerated with no test item related microscopic pathology changes detected.
In the context of this study, Caprinoguanamine showed no evidence of being an endocrine disruptor.
The no-observed-adverse-effect-level (NOAEL) for systemic toxicity was considered to be 160 mg/kg/day.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.